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In humans, morbidity and monality after acute myocardial 
infarction are r&ted to the amount of necrotic cardiac tissue 
subseoueot to the event II). Therefore. treatment of acute 
myo&dial infarction is designed to achieve the salvage of 
ischemic myocardium from eventual necrosis. Reducing the 
duration of the ischemic period by means of early coronary 
roperfusion with fibrinolytic agenls is one way to improve 
xntrictdar function and to reduce the incidence of death 
after acute coronary thrombosis in humans (2,)). Limidng 
ischemic damage to the myocardium directly by reducing 
ischemic or reperfusion injury. oc both, may represent an 
additional approach to reduce myocardial infarct size and 
functional impairment after coronary acctusion and reperfu- 
sion (4). 
In experimental settings, adjunctive treatment with 
thromboxane A2 synthase~inhibition (5) or endopemxide 
rcceotor antanonism (63 ditTerentiaUy attenuates ome of 
the iimitaTions of thrdmbolytic etUca& witb streptokinase, 
such as delayed (6) or law gade (7) coronary reprfusion and 
early coronary reocclusion (5.6). In addition, tbromboxane 
A, synthase inhibitors (8.9) and endowoxide receptor an- 
tagonists (10-14). whengiven separately, have been demon- 
rtrs:cd to reduce myocardial infarct size elicited by cownary 
occlusion and repexfusion in dogs (lO,ll), cats (8.12). rats 
(13) and monkeys (14). However, a combination of throm- 
boxane A, syntbase inhibition with endoperoxide receptor 
antagonism has a greater antiplatelet and antithmmbotic 
effect than has either single intervention or aspirin in I) 
preventing occlusive thrombosis in extensively damaged 
canine carwary arteries (15-17) and rat carotid arteries (181, 
2) epinephrine-induced exacerbations of cyclic flow reduc- 
tions in stenosed cxdne coronary arteries (19),3) enhancing 
thrombolysis with recombinant &sue-type plasminogen ac- 
tivator WPA) and herann in canine corooa~; arteries (20). 
and 4) reducing plateiet hemostatic plug font&on (21,iZ). 
Therefore, we studied I) to what extent a combination of 
strong thrombonane A, synthase inhibition combined with a 
modest degree of endoperoxide receptor blockade enhancer 
slreptokinase-induced coronary thrombolysis in dogs, and 
2) whether this combined therapy also provides salvage of 
canine cardiac tissue after postischemic reperfusion. For 
that purpose, we used two compounds already used in 
humans: 1) strectoslioase, producing librinolysis (23); and 2) 
ridogrel, providing thromboxane Az synthw inhibition at 
low dYses and additional endoperoxide receptor antagonism 
at higher doses (21,22,24). 
Methods 
Sttrgiral procedure. Male or female mongrel dogs (n = 54) 
weighing 18 lo 28 kg were anesthetized with sodittm pentohar. 
bital (30 m&g intravenously). Ahr endotrxheal intuhrdion. 
ventilation was performed with a mixture of 60% oxygen and 
4% nitrous ox& using a Siemens sentoventilator 900 c. The 
left jugular vein wits cam&ted ior the administration of 
compounds. A high fidelity 7F catheter-tipped manometer 
(Philips) was inserted through the carotid artery in the left 
ventricle for measurement of left veotricular pressure, I& 
ventricular end-diastolic pressure and the maximal and mini- 
mal first derivative of the left ventriculw pressure (dP/dt). A 
catheter was inserted through the femoral anety and cannected 
to a F23 pressure tnnduw for the meastt~emettt of systolic 
and diastolic blood pressure. Heal rate was derived from the 
electrocardiographic (ECG) lead 11. 
A thoracotomy was performed through the fiftll interas. 
tal space and the heart was suspended in a pericardial cradle. 
f f, ! FIgme 1. Experimental protocols. A, Coronary 
thmmbolysis. B, Myocardial intkct size.‘*Btood 
sampling; BT, = bleeding time I; BTz = bleeding 
time 2; BT = bleeding time: ET = endotbelial: i.v. = 
intravenously; LAD; let? anterior descending COT- 
onary artery; MS, = first injectjon of m&spheres; 
MS, = rrcottd injection of microspheres. 
The left anterior descending coronary artery was dissected 
free over a length of 2 I cm at I.5 to 2 cm from its origin. An 
electromagnetic Row probe was placed on the aorta (diame- 
ter 16 to IS mm) and another on the anterior descending 
coronary rtrtety (diameter 22 mm); both were conwcted to 
electromagnetic blood Row meters (Sk&u), calibrated in 
literslmin and mllmin. respctively. 
Hemodynamx data were recorded ofi a multicbannei 
recorder and, by means of transducer amplifws, fed into the 
an&g for digital conversion on a Micr&‘DP 11 (Digital 
Eouipment) campaler system and dispkyed on a Macintosh 
computer (Apple Coo~puter, Inc.). 
Fqerimmtal proto&. The experimental protocols are 
summarized in ?igore 1. Baselim nwdings of the heow 
dynamic variables were obtained over a period of 20 tin, 
during which bleeding time was measured and blood samples 
were taken for the determination of serum levels of throm- 
boxane B,, bket~prostaglandin F,, and prostaglandin E, 
and the assessment of coagttlatiw and tibrinolysis variables. 
In the thrombolysis experiments, a constrictor was 
placed on the left anterior descending coronary artery (dim 
ameter I to 1.3 mm) 10 induce a 5t% redttction in How. The 
constrictor was temporarily removed and lhe wall of the 
anterior descending coronary artery was damaged by crush- 
ing it wi.), a forceps. Thereafter. the constrictor was re- 
placed and the coronary artery was occluded for 10 min by a 
clamp placed distally from th; constriclor. On release of ihe 
clamp in the presence of the constrictor, coronary bled flow 
decreased spontaneously to zero because of the formation of 
an occluding thrombus. Persistence of complete coronary 
obstrwtion WE monitored for 60 min. Fifty minutes after 
occlusive thrombuo formation. b!ood samples were taken for 
the measurement of serum pros&aid levels. Thereafter, the 
dogs were randomly assigned to one of the fallowing groups: 
group I (n = i I) received saline solution, 0.2 mlikg intrave- 
nously, to serve as conirol dogs and group 1I (n = 7) received 
ridogrel, 0.31 mgikg intravenously. for thromboxane AZ 
synthase inhibition (17.21.25). Group 111 (n = 7) received 
ridogrel, 5 mgikg intravenously, for thromboxane A, ryn- 
thase inhibition combined with prostaglandin endoperoxide 
receptor antagonism (17.21.25). Cioup IV (n = 3) also 
received saline solution instead of active medication. Ten 
minutes after those treatments. another blood sample was 
taken for detemtination of serum prostanoid levels. There- 
after. thrombolysis was initiated with streptoki?nse. 
I WJO W/kg bum~enously as a bohts injection, f&wed by a 
continuous infusion of 100 IUikgimin during 9c tin (total 
dose IO,OlM IIJikg) in groups I to III. In coutrast, group IV 
received saline solution instead of streptakinase. At the end 
of the streptokiuae infusion. blood samples were taken for 
serum pro&uoid determinations and bieeding times were 
measured. At the end of the experiment (210 mitt atIer 
initiation of thrombolysis). blood samples were again taken 
to determine the serum levels of pmstanoids. coagulation 
and tibrinolysis variables and plasma levels of ridogrel. 
Times required to achieve low grade restoration of COD 
nary blood Row to ~5% but <SO% of the baseline value 
relative to the prethmmbosis values or high grade coronary 
reFerfusion (that is, restoration of coronary blood Row to 
SO% of the baseline value) were recorded; in case no 
coronary repetision occurred tier the admiuistrution of 
streptokinase. the duration of the experimental period 
(210 miu) was used for funher data processing. 
The maximal extent of coroeay blood Row achieved on 
rep&&ion as well us the Row at the end of the experiment at 
210 tniu after exposure to streplokioase were recorded. Addi- 
tiooally, the inciince of I) cyclic repetfusion and reoccl”$” 
paflems characterized by reductions itt coronary blood Row to 
zero Row for <2 mitt before retwied repetfitsion or pemttment 
reocclusion; and 2) complete t’eocclusions. characterized by 
zero ccmnury Mood Row fw al0 miu, were recorded in each 
e&u&e treatment grwp. 
In experiments for the determination of myoeardial in- 
farct size. a small segment of the left anterior descending 
comniwy artery, I.5 to 2 cm from its origin, wus dissected 
l&e. Cornnary artery ligation was performed during 90 min. 
followed by IM mitt of repwfusion. 
Ridogrel, 5 m#kg intravenously (n = IO), or solvent, 
0.2 mbltg intraveuously (n = 9). was given iotavenously 
30 mitt after the onset of coronary occlusion. Regional 
myowdial blood Bow was measured 25 min after left 
unlcrior descending coronary artery occlusion just before 
the administration of solvent or ridogtzl and again at the nd 
of the occlusion period; for that purpose, 15.~ radiolabeled 
micmspheres (cesium-141, stannum-113, ruthenium-103 and 
niobium-95j were injected tuto the left attiuut (Fig. IB). 
At the end of the experiment, the rnimals were killed with 
ao overdose of sodium pentobarbital _’ 1 myocardial infarct 
size and area at dsk were measured using B combined Evans 
blue-triphe”yltettazoli”m chloride stain&g technique (26). 
The accuracy of the hiphe”yltetwoli”m chloride method in 
identifying infarct size in the experimental conditions of the 
present study has been described elseabere (26). The area at 
risk for myoardial itdarctioo after wckaical coronary 
artery occlusion (98 min) and sutwequent repetfusioo 
(I50 min) is expressed as a percent oftbe total mass of the 
left venttic!e. !ofarct size is then expressed as a percent of
the area ar risk in each attimal(26.27). 
Tbrornbo~ Al 
ceptor antagoaisol b f0 
inhibit platelet thrumboxane A2 synthax was assessed by 
measuring its effect 0” seruut prostanoid levels. Fbr the 
detemdnation of serum pmstanuid levels. venous whoIe 
blood (I .6 ml) auticoasulated with sodium citrate (0.38%) 
was warmed to 3’PC (I6 mi”) and coagulated (I hat 3PC) by 
the addition of calcium chloride (0.2 ml: I x IO“ mol!Xter 
final concentration) at&d thmmbin’(0.2 mi: 20 HIH U/ml tktai 
concentration). ThereaRer. cell free seturn was prepared by 
repeated centrifugations (I5 mitt x 350 g; 5 udtt x IO,CtO8 g) 
and stored at -25°C. Serum levels (n&d) of tbromboxutte 
B,. bketo-prostaglandin F,, and prostaglandin & were 
assessed by radiiimmunoassay using specific antisera and 
tritiated tracers (21.253. 
Antagonism by ridogre of canine platelet thmmtmxane 
AZ and p~astaglundin endopemxide receptors at plasma 
levels of the compound achieved alter its in viva adminis- 
tration was assessed usiog platelet aggregation expexittws. 
For that purpose, the inhibition by ridogre!, I to ICJI @ 
liter, of canine platelet aggregation, triggered by U-?&N9 
after presensitization with lepinephrine, was measured in 
vitro as described p&o”sly (17.20). Briefly, 0.4 ml of 
titrated platelet-rich plasma was itxubated (10 mm at roam 
temperature and 5 tniu at 3X) with 0.05 ml of HEWS 
btier (200 mmollliter, pH 7.5) attd 0.05 ml of solvent or 10 #I 
of ridogre (I to 100 urn&liter) suuplemented with 0.01 ml of 
I-epis&ti”e (10 &Miter, 2 ;;lin at 3X) before the 
addition of U-t6619 (I umobliter) aud the measurement of 
the reaction in an ag&ometer. The extent of the platelet 
response was measured by calculation of the speed of 
increase of light tm”smissia through the stirred sample 
(slope in % tr&missionlmin). Percent inhibition of U46& 
tti@ered platelet aggre8”tio” by ridogrel was calculated 
versus reactions in @red solvent-treated samples. 
Plttstua~attdWimly&. Toaswspharmuco- 
logic eBects of treatment on p&ma coagula& and fibrin- 
ogenolysis, the activated partial tbmmbopkain time and 
plasma fibrinogen kvels were assayed on cihated pktekt-wr 
plasma obtained from b!aod supplemented with aprotinitt 
(I.OWl W/ml) “sing mutine medures (28). Plasm” fibrinogen 
levels were expressed in mgllW ml. Values afler medication 
were cxxupwed tith the pretttedication values in the same 
dogs. 
A possible iotluence of ridogre on the enzymatic path- 
ways involved in streptokinase-induced tibrinolysis ‘w 
checked “sing a diluted whole blood clot lysis test on canine 
blwd. Briefly, canine ciliated (sodium citrate 0.013%) blood 
was diluted l/IO with ice-cold 0.07 mol!liter ohosohate buffer 
pH 7.4. containing 0. 1.2.X 5 or 10 Wlutlbf s&Nokinase 
and 10 pmoliliter of ridogrel or its solvent (0.15 moliliter of 
sodium chloride), incubated for 5 min at 37’C and thereafter 
coagulated with thrombin (2.5 NIH U/ml). After further 
incubation (1 h at 3X), the residual clot was rinsed with 
0. I5 mol/litcr of soaium chloride, dissolved in 0. I N of potas- 
sium hydroxide and quantified by a photometric assessment of 
its hemoglobin content. The enzymatic tibtinolytic activity of 
streptokinase is reflected by the size of the residual clot and is 
expressed as a percent of a nonlyscd control sample. Value+ in 
the presence of ridogrel were compared with those obtained in 
the presence of solwtt (2.5). 
Hemostasis. Tbe e&t of treatment on bleeding time was 
determined using a spring-loaded blade device (Simplate II, 
General Diagnostics) (29). Incisions were made on the dorsal 
side of the left shaved foreleg and blood was blotted until 
bleeding had stopped for B I mitt or for 30 min when bleeding 
continued. Bleeding times were recorded in seconds; those 
>30 min were recorded as equal IO l,80l s. Values recorded 
after the administration of solvent or ridogrel were compared 
with the premeditation values obtained in the same dog. 
Morphologic study. Using light microscopy, damage to 
the vessel wall and the subsequent hrombus formation were 
evaluated in dogs in group IV (n = 3) receiving no active 
treatment. At the end of the experiment (270 min after 
initiation of thrombosis), a Zcm long segment of the left 
anterior descending coronary utery wilh Ihe constrictor in 
place was excised and immersed in a mixture of 2% 
pamformaldehyde and 2.5% gltttaraldehyde in phosphate 
buffer (pH 7.4) for 224 h. The areas of the left anterior 
descending coronary artery under, proximal and distal to the 
constrictor were separated, segmented and rinsed at 4°C in 
2% osmium tetronidc in 0.0s mol/Iiter of Verona1 acetate 
buffer (pH 7.4) containing 3.2% sttcrose. After rinsing in 
0.05 molAiter of Verona1 acetate buffer supplemanted with 
7% sucrose (pH 7.4. 4C) for 5 min. the tissue was impreg- 
nated with 0.5% uranyl acetate b&r (pH 5.2) for 40 min at 
4°C dehydmted in graded series of ethanol and embedded in 
Epott. Transverse sections, 2 (rm thick, were prepared and 
stained with toluidine blue for microscopic analysis (17). 
Statistical analysis. Results are expressed as mean value 
2 SEM for continuous data. Baseline values of the herno. 
dynamic variables in the experimental groups were com- 
pared using analysis of variance (ANOVA). Time to event 
otcesorctnents are represented as median values and 95% 
conftdcnc- limits based on the binomial distribution. Non- 
gausbian data were analyzed for intergroup comparisoos by 
means of e two-t&d Mann-Whitney 6 test (30). Counted 
data were analyzed t, the Fisher exact probability test. In 
all statistical procedures, Bonferroni’s inequality was used 
to correct for multiple comparisons. Analysis of covariance 
with perfusion area as the covariare was used lo assess the 
effect of treatment on myocardiai infarct size (31). The tire 
course of potential effects elicited by the administration of 
solvent or compounds on hemodynamic variables and myo. 
cardial blood Row was analyzed using a multivariate 
ANOVA for repeated measures (32). 
Morpbohgic study. Light microscopic analysis of leti 
anterior descending coronary artery segments revealed cx- 
tensive vessel wall damage associated with osclusive throm- 
bus formation. In con&t to the rather normal appearance 
of distal seaments without crush iniurv. disconnection of the _ 
elastica intemafrom the vessel wall, disruption of the media 
and focal insudation of red blood cells and polytxorphomt- 
clear white cells were prominent in arterial segments under- 
neath the coronary constrictor. The occlusive thrombus 
adhering to the site of vessel damage consisted of a mixture 
of platelet aggregates, intermingled with fibrin threads en- 
trapping red blood cells, and was infiltrated with polymer- 
phonuclear cells (Fig. 2). 
Coronary rhrombdyb. Baseline hemodynamic variables 
(heart rate, systolic blood pressure, diastolic blood pressure, 
maximal and minimal first derivative of the left ventricular 
pressure fdP/dt), IeR ventricular end-diastolic pressure and 
flow values in the left anterior descending coronary artery 
before and after coronary stenosis) were not significantly 
different among the various experimental groups (Table I). 
In the control period, coronary blood flow showed a 
stable asd constant pattern. Slenoris of the coronary artery 
at the site of crush injury to the vessel resulted in an 
occlusive thrombus within 20 mitt in all preparations. At this 
point in the exprtimcntal protocol, seven dogs were ex- 
cluded from further analysis (in three dogs, development of 
a thrombotic elusion persisting for 60 min did not occur; in 
another four dogs, de&h occurred shortly after coronary 
thrombosis as a result of ventricular fibrillation). 
After the administration of solvent or rid&l and subse- 
quentinfttsiin ofstreptokirwe@roupsI, 11 and Ill).beartrate 
remained constant and blood pressure decreased slightly attd to 
a similarexrcnt in all groups. A rli$t decIcase in I& venlric- 
alar perfommce ~mmimal and mmtmal MI ventricular dP/dt) 
occurred in all groups during the total obsctwtkm period 
relative to the value before thrombosis. 
The pattern of coronary reperfusion (Fig. 3) and the 
overall etiicacy of thrombolysis elicited by streptokinase 
were markedly influenced by the adjttnctive treatment given 
in addition to the tibrinolylic agent: both doses of ridogrel 
were superior to solvent (Table 2, Fig. 3 to 5). Resroration of 
blood tlow >5% but <Xl% of the orethrombosis values (low 
grade rcperfttsion) occurred in 7 $3%t of I I solvent-&ted 
dogs (group 1) but in all animals receiving ridogrel in a low 
dose (group 11) or a high dose (group 111) (p < 0.05 vs. 
solvent). In contrast. hii grade coronary rep&ion >50% 
of the prethrombosis level was achieved with stwtokinasc 
in 3 (a%) of II solvent-treated dogs, in 5 (71%) bf 7 dogs 
receiving ridogrel at a low dose (0.31 @kg intravenously: 
p < 0.05 vs. solvent) and in all 7 (IO@%) of 7 dogs given the 
Figure 2. Transverse sections of the kit 
anterior descending coronary array 
outride (a) and under (b) the constric- 
tar. a. Normal morphology of the vas- 
PI lar wall showing a nanintem!pted in.
terna: elastic lamina (arrows). b, In this 
area under the constrictor, part of the 
internal elastic lamina (arrow) is discon- 
nected fro,,, the vessel wall and SW- 
rounded hy P,&etet-rich tbmmbw ma- 
terial (TM): the thrombotic wclusion of 
the artery is nearly complele. Ma&i- 
cation x45, reduced by 20%. A = ad- 
ventida; M = media. 
highest dose of tidogrel(5 mgkg intravenously; p < O.OS vs. Wmination of the experiment (Fig. 4, lower tight panel) 
solvent) in addition to streptokinase (Table 2). were significantly higher with both doses of ridogrel relative 
The duration of streitokhmse infusion required to 
achieve a low grade coronary rcpertkion was signifitantly 
shorter with both doses of ridogre as adjunctivc medication 
in cmnpaison with solvent (Fii. 4, upper left panel). How- 
ever, the infusion period of stqtdiinase to reach high grade 
coronary reperfoiion was si&ficantly shorter in dogs 
treated with the hinhest dose of ridoerel fmediin 37 min) 
then in those receking the lower d&e of the compound 
(median 85 mitt) or solvent (median 210 mint (Fig. 4, upper 
risht panel). The ma&at extent of coronary reperfusion 
achieved during the experimental period (Fig. 4, tower IetI 
panel) as well as the eventual level of coronary bloat Row BI 
to solvent. 
1 he incidence of cyclic repafusion and reocclusion was 
significantly lower in- dogs rkving adjunctive treatment 
with either dose of rid-1 (four lS7%1 of seven dogs with 
0.31 m&g and three [4?%] of seven with 5 m&g) than with 
solvent (six [8S%] of seven) (Table 2). 
Moreover, in dogs treated with streptokioase. the ioci- 
dence of permattent reocclusion within the experimental 
observation period was sigoiicaotly lower with ridogrel, 
0.31 ogkg (two [XV61 of seven) and ridogrel, 5 m&z (one 
[14%] of seven), than with solvent (five 171%1 of seven) 
(Table 2). 
In the three dogs receiving solvent 88 adjunctive inter- 
vention and solvent instead of active thmmbolytic treatment 
(group Iv), no coronary reperfusion occurred during the 
experimental period. 
Myaewdial infarct size induced by meebmtkal mrcmuy 
oeduiao end reperh~&~~ In comparison with that of sol- 
vent (n = 9). the intravenous administration oi tidogrel 
(5 mg/kg; n = IO) 30 min after coronary occlusion elicited no 
significant changes in hemodynamic variables recorded dur- 
ing mechanical coronary artery occlusion and subsequent 
reperfusi~n. Myocardial collateral blood Row in endocardial, 
tttidmyocardial and epicardial areas atIer 7.5 min of eoronmy 
occlusion, that is, b-fore the administration of solvent (total 
collateral flow 14.2 ? 6.2 ml/100 g per min) or ridogrel(14 2 
8mLloOg per&), and attermination oftheischemic period 
(IO + 9.2 ml/IO0 g per min in the solvent-treated group; 
13.3 + 7.3 ml/l00 g per min in the ridogrel-treated group) 
were comparable in both groops. Areas at risk for myocar- 
dial infarction after coronary occlusion and reperfusion were 
Tsbk 2. Etkcts of Adjunctive Medication cm the 
Tbrombolytic Efficacy of Streptokinasc in Thmmbased Canine 
Comnarv Arteries 
P&we 3. E&t of adjunctive medication on 
the time course of reperfusion during strep 
tokiinase-induced thmmbolysis of canine COT- 
0nary arteries. Occlusive thrombosis (60 min) 
was induced by crush injury stasis (IO min) in 
stenosed coronary arteries. Adjunctive intra- 
venous (i.v.) medication (solvent, n s II: 
ridogrel, 0.31 m&g, n = 7; ridogrel, 5 m#k& 
n = 7) wa?; admmistered SO min after initiation 
of tbmombxis and 10 min before intmvenous 
adndnir!ration of streplokinase (I,Om Nlkg 
b&s injection; 100 NJ/kg per min during 
90 mitl). Itat8 tim represent the mean values 
of seven or more expcrimenb. p c 0.0s 
wrws s0,ve.t far the toteI time munc of 
coronary reperfusion with ridogrel. 0.31 and 
5 rntig intravenously. LAD = left anterior 
descending comnai~ artery. 
similar in dogs receiving solvent (a,, I at risk 33.2 + 2.1% of 
the left ventricle, n = 9) or ridogre (area at risk 36.3 f I .5% 
of the left ventricle, n = 10). In contrast, myocardial infarct 
size at the end of the reoerfusion G&XI was significantly 
@ < 0.05) smaller atler idogre (it&t size 29 g 3.9% of 
area at risk) than atIer s&ent (infarct size 49.3 +_ 4.3% of 
area at risk) (Fig. 5). 
@o&m by &. ‘In dogs&e&solvent ai adjunctive 
tr&ment befor; streptokinase (goup I, n = 10, levels of 
thromboxam B, (before 244 f 17 n&k et 210 min 256 * 
24 &I), pro&&din F2. t.befok 2.7 t; 07 n&k at 
210 mitt 3.7 f 0.4 o&d) and Cketo-pmstaglandin F,, 
(before 4 f: I n&l; at 210 min 9 f 5 “g/ml) in serum of 
spontaneously coagola:ed whole blood remained cornpam 
ble before and at various intervals up 10 210 min after the 
initiation of tibtinolysis. 
In contrast. serum levels OF thromboxane BS were TC- 
duced sigttiticently and to the same extent et v&us inter- 
vals after the low dose (0.31 mg/k#; group 11) of ridowl 
(before 1% * 44 nplml: at 210 min 56 c 23 w/ml) and the 
high dose (5 mg&; group III) of the com&nd (before 
25 + 55 t&l; at 210 min6 ? 2 n&l) in comparison witb 
premedicalion values. Serum levels of pmsta&ndin E2 were 
significantly and to the same extent higher after ridogrel, 
0.31 mglkg: before 5 + 1 I&& at 210 min 151 f 30 ng/ml; 
and after ridogxl, 5 n&g: before 4 ? 1 &ml; at 210 min 
218 * 55 n&n!. Likewise, swum levels of 6-keto- 
prostaglandin F,, were significantly higher than pretreat- 
ment values after both doses of ridogrel (ridogrel. 
0.31 m&g: before 3 + 0.2 ng/ml; at 210 min 19 2 5 ng’dl: 
lidogrel, 5 mg/kg: before 3 ? 0.3 nglml: at 210 min It3 L 2.4 
@ml). 
Plasma levels of tidogrel wefe 1.65 f 0.2 and 0.48 2 
0.1 lrglml at IO and 210 min. respectively, after the 
0.31 mgnts dose @oup II) and reached values of 30.9 + 2.3 
. . 
..r 
.* 
and 27.5 + S.9 p&d at those intervats after the 5 mgkg dose 
(gmup 111) in dogs subsequently treated with streptokinase. 
In vitm. concentrations of ridogrel matching the highest 
&ma level (1.65 w/ml or 0.45 umobliterl obtained after 
ihe 0.31 “t&d& &rgi”ully reciuced the extent of aggre- 
gation induced bv U-46619 (1 pm&liter) in ciliated canine 
platelet-rich plasma presensitized with a subthreshold con- 
centration of I-epinephrine (IO ,uuwVliter). In contrast, such 
a platelet reaction was substantially inhibited (27.1 ? 4.7%: 
p < 0.0s vs. solvent) by ridogrel in vitm at a concentmtion 
matching the highest level obtained after the 5 mgikg dose in 
viva (30.9 &ml or 8.5 p&liter). 
Coagulation, tibrtudysir pnd hem&&. In dogs receiv- 
ing solvent (group I), low dose ridogwl &roup II, 0.31 mgjkg) 
or high dose ridogrel (group III. 5 mglkg), thrombolyris with 
streptokinase also produced a reductiun in the plasma coag- 
ulatlo” apxity “s reflel;ted by a significant prolangaion of 
the activated partiai thromboplastin time (Fig. 6A) and 
tibrinogenotysis as evidenced by a significant reduction in 
plasma fibrinogen levels (Fig. 6B). However, the extent of 
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Figure 4. E&et of adjwetive medication on nperfurio” variables 
during srreptokiuase-induced tbmmtnlvsis cf Fanine cwonary at- 
tertesand oFctusivcthmmbusis WJmid induced by cmshinjuryand 
stasis (IO minf in stmosed curcmary arteries. Adjunetive inWave- 
“eus medication Went, n = It: rid*& 0.31 mgikg, n = 7: 
ddogrel, 5 mgikg. n = 7) was administered 50 mi” after initiation of 
lhmmbosis and 10 tin bsfwe inlravswus administmtiu” OF strep 
tokinase (SK. t,ooO W&g b&s injection; IW W/kg per mi” 
intravenously during W min). Upper panel, Time after initiation of 
srreptokinase administrotton to reach repcrfusion. Lower wet, 
Extent of maximal Max) cornnary reperfustca (LR) and coronary 
Row at the end of the experiment Wght) es Y ,xxe”r dprethmm- 
b&s values. l p < 0.05 versus .olvcnt. = individual values; - = 
media” wlues. 
such changes was similar in all groups. Template bleeding 
times were prolonged signi6cantly after the administration of 
streptokinase in animals additionally treated with sotvent 
(group I). Rid@@ in the low dose of 0.31 mgjkg (proup 11) 
produced no funber statistically significant pro!ongation 
relative to solvent. By contrast, high dose ridogrel (group 
@we 5. Reduction in myocardial infarct size (IS) after ddogrel 
without effect on the area at risk (AR) in comparison with solvent in 
dogs with mechanical left anterior descending coronary occlusion 
PI min) followed by reperfusion (150 mini. Solvent (n = 9) or 
ride@ (5 m&g intravenously [Lv.], n = IO) was administered at 
25 min ofocetusioe. l p < 0.05 versus solvent. L,V = lek vcntrtete. 
III) resulted in template bleeding times signiRcantly longer 
than those recorded after solvent or the law dose of the 
compound in dogs treated with streptokinase (Fig. 6c). In 
vitro, lysis within I hat 37°C by streptokinase (0 to 10 U/ml) 
of l/IO diluted canine whole bldod &ted with thrombin was 
identical in the oresence of tidoerel (10 vmolIlit.4 or its 
solvent (results not shown). - ’ 
Discussion 
The present study demonstrates that pharmacologic ma- 
nipulation of arachidonic acid metabolism and receptor 
effects, when appropriately balanced in terms of spe&ic 
thmmboxane A, synthase inhibilios and additional ettdooer- 
oxide receptor ~niagonism has two important actions. i) II 
substantially enhances the thrombolytic eflicacy of strep 
tokinase; and 2), as a complementary effect, provides sal- 
vage of cardiac tissue from reperfusion damage subsequent 
to mechanically induced myocadial ischen& at the &se 
upgrading the thrombalytic efficacv of stremokinase in an 
optimal fashion. 
Indeed, the overall efficacy of thrombolysis achieved with 
streptokinase against occlusive platelet-rich corontuy 
thrombi is enhanced when tidogxl is used as an adjtmctive 
medication to the fibrinolytic aged. Such an upgrading of 
thrombolysis is evidenced by the shorter period of tibrino- 
lytic treatment required to reach high grade reoerfusion, the 
increased incidence and extent of ma&al cornnary reper- 
fusion as well as the reduce? owtrrence of reocclusion in 
animals receiving ridagrel compxed with solvent in addition 
to streptokinase. Moreover. the substantial difference in 
etlicacy in that respect between the low and high dose of 
cidogrel as adjunctive interventions points to a positive 
B 
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Ftgun 6. Effect of streptokinw and adjonctive medication on 
plasma coag!Mion. tibdncgenc4ysis and ticding time in degs 
subjected to coronary thmmbolyais and ecclwive thrombosis 
(6Omin) induced by crushinjury stis(lOmin1 in rtenesed cerenary 
arteries. Adjunctive intraveeaus medication (solvent, o = II: 
ridogrel, 0.31 m&g, n = 7; ddogrel, 5 m#kg, n = 7) was adminik 
tered 50 min after initiation of tbmmboris and 10 min before 
intravenous administration cd st~piokinese WBI IUfkg b&s 
in&lion: IW W/kg psr min during 90 mitt). Activated partial 
thromboplastin time (AFIT). plasma Rbrinoptn and bkcdii time 
we reported es “tee” values ? SEM. @en bus = values Were the 
administration of adjunctive medication (solvent 01 ridogrel) and 
streptdrinase: htckd bars = values at the end of the experiment. 
*, **p < 0.05 versus values *before streptokinarc administration or 
**with solvent. 
interaction between thmmboxane AI syttthase inhibition and 
endoperoxide receptor antagonism in improving coronary 
reperfusian and maintaining patency with streptokinase. 
Low dose ridogrel (0.31 mglkg) strongly reduced serum 
levels of thmmboxane 8, and increases those of Cke~ 
prostaglandin F,. and pros@landin E, throughout the ex. 
p&mental period. In contrast, at peak plasma levels of 
ridogre reached by this dose, aggregation of canine plate- 
lets, sensitized with I-epinephrine and subsequently stimtt- 
lated with the thmmboxane A, mimetic U-46519 (17.20), is 
only marginally at&ted. Although by no means reflecting 
actual in viva levels (33.34). the reduction in thromboxane 
9, levels and rhe reorientation to increased levels of bketo- 
p&&ndin F,, and prostaglaodin E, as measured by 
radioimmtmoassays in serum from ccagzlated blood ex viva 
demonstrate the capacity for profound and specific throm- 
boxane A, synthase inhibition of ridogrel in a low dose, 
lacking substaatia! endooeroxide recrptor antagonism 
(17.25). As documenred earlier with alternative molecules 
(5), such thromboxane A, synthase inhibition to some extent 
improves streptokinase-induced thromholysis. Thts is re- 
flected by the shorter time to reach reperfusion and the 
greater extent of maximal reperfusion obtained with such 
adjunctive medication in comparison with solvent. How- 
ever, the enhancement of the thrombolytic efiicacy of strep- 
tokinase obtained by such thromboxane AZ synthase inhihi- 
tion is less pronounced than that achieved with high dose 
ridogrel. This diE’erence is roost marked on variables such as 
time delay to high grade reperfusion, the incidence and 
maximal extent of coronary recaoaliration and the reduction 
in the rate of rewclusion. In contrast to the :ow dose. the 
high dose of ridogrel provides additional antagonism of 
platelet thromboxane Arprosta&ndin endoperoxide recep 
tots in addition to thrombxane A, synthase inhibition. This 
is evidenced by the reduction in serum thmmboxane Bz and 
the increase in bketo-prostaglandin F,, and pmstaglandin 
E, levels ex viva similar to those obtained with the low dose 
and, in contrast to the latter, by the attenuation of U-46619- 
induced canine platelet aggregation in vitro at concentrations 
of ridogrel equal to peak plasma levels of the compound in 
viva after the administratioo of S mglkg. 
Single endoperoxide receptor antagonism to soroe extent 
improves coronary thrombolysis by streptokinase in dogs 
(6). However, in the present experimental conditions of hii 
thmmbvgenicity due to the presence of a lysing thrombus 
exposing absorbed thmmhin (3.5). such a pharmacologic 
effect is not likely to be the sole mechanism by which high 
dose tidogrel optimizes the etlicacy of the librinalytic agent 
for several reasons. I) The enhancement of thrombolysis 
versus that in a control group with a similar dose of strep- 
tokinase obtained with single endopxoxide receptor antag- 
onism using sulotrohan (6) is less pronounced than thtu we 
achieved in the present study with high dose ridogrcl in a 
similar canine pmfocol. 2) Despite a potency of the throm- 
bwane A, and prostaglandin endopemxide receptor antag- 
onist far beyond that of ridogrel at the highest dose we used 
in the present study (?5). single eodopemxide receptor 
antagonism with sulotmhan (6) is inferior to strong throm- 
boxtine A, synthase inhibition complemented with complr- 
atively modest endopemxide receptor antagonism (ridogrel. 
5 mg/kg) in preventing coronary occtusios in conditions of 
high grade thmmbagenicity created by extensive vessel wall 
damage in dogs (17). 3) Although single thromhoxane AZ 
synthase inhibition (20) or endopemxide receptor .mtago- 
uism (36-38) to some extent enhances the efficacy of core- 
nary tiuombolyris with recombinant tissue-type plasmino- 
gen actwator @t-PA) in heparioized dogs, such an upgrading 
is : ignificantly higher with combined thromboxane 4 syn- 
thase inhibition and eudoperoxide receptor antagonism as 
achieved by compound combioatioos or by dual~aetiog 
ridogrel in comparison with the single interventions (20.38). 
Gf particular interest is the observation that in contrast to 
that of rtPA (39). the enhancement of stxptokinase-induced 
thromholvsis with ridomel occurs without additional admin- 
istmtion bf heparin. %ilar to conditions dxing primary 
prevention of thrombus fommtion in dawged coronary and 
carotid arteries of vaticus species (IWO), the present data 
sugest that thmmboxane A2 syothase iohibition, by reori- 
enting prosmglzndin eadopemxide metabcdism away from 
thromboxaoe A, into the inhibitory prostaglaodin 9 and 
prostacyclin, synergizes with modest eodopemxide recexor 
antagonism. blocking the shutdown by accumulatir@ p’os- 
taglandin endoperoxides on adenylate cycla?.e by which 
inhibitory prostanoids increase platelet cyclic adettosute 
monophosphate (40). By such a mechanism, this dual phw 
macologic intervention on arachidooic acid metabolism and 
receptors sigoi8cantJy attenuates platelet activation during 
streptokinase-induced coronary thrombolysis. Such au iohi- 
hition of platelet reactivity is sufficiently strong to reduce 
renewed deposition of thrombotie material on the lysing 
thmmbas, thereby accelerating aad intensify@ coronary 
recanalization and preventing thrombotic rwcclusion after 
streptokinase. We observed that streptokinase-induced 
changes in plasma fibrinogen levels and in activated partial 
thromboplastin time as well as the lysis by strepiokinase of 
diluted canine whole blood are uot iolluenced by ridogrel. 
whereas template.induced bleeding times areproJot&!ed after 
the highest tidogrel dose. This observation points to aa 
action of high dose ridogrel on platelet function for enhanc- 
ing streptokinase-induced thtmnholysis rather than on tka 
activity of enzyms involved in the ccqulation and fibrin- 
olysis cascades. 
At the dose of 5 mglkg, ridogre produces Combitted 
thromboxsne AZ synthase inhibition and endopemxide R- 
ceptor antagooism. and thereby optimal enhancement of the 
thmmbolytic ef&oacy of streptokinase iu restoring and main- 
taining coronary artery pate& Thus, at this dose, ridogre 
sienilicaotlv reduces the sire of the mwwdid infarct re- 
siting from a mechaoical left anterior descending coronary 
artery occlusion followed by coronary reprfosion. The 
.sbsence of effects of combined thromboxaoe Al syuthase 
.nhibiwn and edopemxide receptor antagonism with 
ridogrel on heart rate. blood pressure, cardiac prfomtaoce 
and regional myocwdii blood flow argues against a relevant 
contribution of major hemodyomnic effects of this agent on 
the preservation of myocardial tissue sod points to localized 
myocardial sites of action during isehemia and reperfusion. 
The myowdial salvage we obtained with ridogrel at a 
dual-acting dose may be due to I) thromboxaoe A2 synthase 
inhibition, reorienting prostagiaudin eodoperoxide metabo- 
lism away from tkromboxaoe AZ into imreased amoaots of 
protective prostaghodin VT and prostacyclin (9.43, or 2) 
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eudoperoxide receptor antagonism, blocking detrimental 
cellular responses to prosta&mdin endowoxides and 
thromboxane A2 (8,10,11,14), separately shown to reduce 
myocardial iufarct size after coronary occlusion and reper- 
fusion, or 3) the combination of thromboxane AZ synthase 
inhibition and endowoxide receutor antaeonism (17). l’be 
protection against ~y&dial rep&fusion i&uy by the latter 
phamhwologic intervention then may be a result of several 
possible effects, including reductions in microvascular vaso- 
spasm (42). platelet activation (42). cytotoxicity and lysoso- 
mal enzyme release (8,43) and neutrophil accumulation and 
activation (44-47). 
Concbsious. The present study demonstrates that pro- 
found thromboxane A, synthase inhibition combined with a 
comparatively modest degree of ettdoperoxide receptor au- 
tagonism as achieved with ridogrel in doses applicable to 
humans (24) significantly enhances the efficacy of coronary 
thromboly% elicited with streptokiuwe, even without the 
concomitant application of hepwin as adjunctive medica- 
tion. Moreover, in cmtttast to cyclooxygenase inhibition 
(48,49), such a pharmacologic inte&entio~~providw salvage 
of myucardial tissue at risk of infarction because of coronary 
occlusion and reperfusion. This observation may have im- 
plications for the future treatment of oatients with acute 
&yocardifd infarction. 
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